ASCO 2026版Ⅳ期无驱动基因突变非小细胞肺癌治疗动态指南
专家组整合既往更新,形成循证推荐,关注疗效与安全性。
要点
- 指南覆盖无驱动基因突变Ⅳ期NSCLC的一线、二线及后续治疗。
- 推荐由多学科专家组依据系统综述与非正式共识制定。
核心结论
- 指南针对无驱动基因突变的Ⅳ期NSCLC,更新了一线、二线及后续治疗的循证推荐。
研究设计与样本
- 专家组由肿瘤内科、肺科、社区肿瘤、研究方法学及倡导专家组成,检索包括系统综述、荟萃分析和随机对照试验。
主要发现
- 最新文献检索共识别出6项新的随机对照试验。
- 指南整合了所有既往更新,反映了支持该主题的证据体系。
临床怎么用
- 临床可依据该指南为无驱动基因突变的Ⅳ期NSCLC患者选择一线、二线及后续治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations. METHODS: This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Six new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS: Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
引用
- Reuss JE, Bazhenova L, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0. J Clin Oncol. 2026. PMID: 41632927. doi:10.1200/JCO-25-02825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。